During the past decade, Merck Sharp and Dohme de Espana S.A. conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Merck Sharp and Dohme de Espana S.A." are "Advanced Cancer" (1 trials), "Advanced Solid Tumors" (1 trials), "Anal Cancer" (1 trials), "Anal Carcinoma" (1 trials) and "Bile Duct Cancer" (1 trials). Many other conditions were trialed in "Merck Sharp and Dohme de Espana S.A." in a lesser frequency.

Most popular intervention types in "Merck Sharp and Dohme de Espana S.A." are "Biological" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Aprepitant" (1 trials), "Ondansetron" (1 trials) and "pembrolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Merck Sharp and Dohme de Espana S.A." are 2 trials for "All" genders.

Currently, there are NaN active trials in "Merck Sharp and Dohme de Espana S.A.". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Merck Sharp and Dohme de Espana S.A., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Merck Sharp and Dohme de Espana S.A., 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".